Background: Perimembranous ventricular septal defect (pmVSD) is a common congenital heart disease. Transaxillary occluder device closure of the pmVSD has been proved effective and an alternative to surgical closure. The study aimed to evaluate the immediate operation outcomes and the early and midterm follow-up outcomes of transaxillary occluder device closure.
INTRODUCTION
Congenital heart disease (CHD), as one of the lethal birth defects, mostly causing morbidity and mortality of ~0.8% live-born [Bouma 2017 ]. Ventricular septal defects (VSDs) are a common type of CHD with a high incidence. If left untreated, severe morbidity and mortality may develop with or without an evident symptom for most of the time.
With advances in surgical managements and skills, open heart surgical repairment has been considered the golden standard treatment for closing a VSD, having achieved excellent outcomes till now [Green 1965; Hufnagel 1965; Hong 2018,] . However, postoperative cardiopulmonary bypass (CPB) complications and incision scars come along with its good results. Percutaneous transcatheter closure of perimembranous ventricular septal defect (pmVSD) developed, avoiding CPB and incision scar [Patel 2009; Polat 2016; Narin 2018] . Despite the obvious advantage of its minimal effect, the potential damage of radiation and contrast agents, especially for young patients, even complete atrioventricular block (AVB), could bring patients to bad situations [Bai 2015; Karaçelik 2015; Ghosh 2017] . After combining the merits of surgery and the internal transcatheter, minimally invasive periventricular device closure of the pmVSD appeared [Xing 2009; Ou-Yang 2015; and was widespread fast when initial experience proved its safety and feasibility.
In this study's technique, distinguishable from traditional transthoracic device closure, we performed the technique via a right infra-axillary approach, an invisible incision. Here, we report our initially clinical experience and midterm follow-up results. 
MATERIALS AND METHODS
From January 2014 to December 2017, we retrospectively analyzed the patients diagnosed with a single pmVSD in outpatient setting undergoing transaxillary device closure of the pmVSD at Children Heart Center, Henan Provincial People's Hospital. All patients were assessed by transthoracic echocardiography (TTE; Philips iE33, Koninklijke Philips N.V., Amsterdam, The Netherlands) in outpatient setting. The echo measure was completed with the aspect of defect size and defect type with parasternal long-axis and short-axis views, apical 4-chamber view, and apical 5-chamber view. The patients can be considered candidates in this study as long as they were aged more than 6 months. The inclusion criteria includes preoperative TTE evidence of left ventricle enlargement, defect size of 3-6 mm, obvious left-to-right shunt with higher than a 3/6 systolic murmur, distance of superior rim to right aortic valve ≥2 mm, TTE evidence of pulmonary artery systolic pressure less than 30 mmHg, cardiomegaly on chest x-ray imaging, and failure to thrive according to literature. The written informed consent was obtained from patients' guardians, and the medical ethics committee of our hospital approved the study.
Patients with prolapse aortic cusp, aortic valve regurgitation, malalignment of superior and inferior rims, an amount The Heart Surgery Forum #2018-2185 E114 of less than 2 mm of superior rim to aortic valve, history of infective endocarditis, and necessity of cardiopulmonary bypass with other concomitant cardiac anomalies were excluded from enrollment.
Each patient included had the examinations of 12-lead electrocardiogram, chest x-ray imaging, TTE, and blood test before operation.
The preoperative TTE showed moderate-to-severe tricuspid regurgitation (caused by left-to-right shunt) in 9 patients and mild aortic regurgitation (without prolapse aortic cusp) in 2 patients. The general characteristic of all patients are shown in Table 1 .
Device and Delivery System
The device and the delivery system utilized in this study are made by Lifetech Scientific (Shenzhen) Co., Ltd. (Shenzhen, China). All occluders used were symmetrical and double disc self-expandable, made of 0.005-inch nitinol wire mesh and fabric inside. The diameter of the disc is 4-mm larger than that of the waist, and the height of the device is 3 mm. The hollow guide steel was made by us (all are shown in Figure 1 ). 
Procedure
Transaxillary device closure was performed under general anethesia in the operation room. The patient was in supine position; the transesophageal echocardiography (TEE) probe was inserted into the esophagus to confirm size and type of VSD ( Figure 2 ). Once confirmed, the position was transferred to the left lateral position to offer a good exposure of the right armpit. According to previous TEE result, the occluder was chosen by adding 0-2 mm to max-VSD diameter (that is, to the maximum chosen from diameters of different echo views).
The patients were usually administrated with heparin (1 mg/kg). A 2-3 mm mini-incision between the third and fifth intercostal space was made, through which the thoracic cavity was entered. After opening the upper part of the pericardium and suspending the pericardium, the heart was well exposed. The puncture site was located 2 cm over the atrioventricular gap, around which the U-like suture was sewn. The hollow guide steel was advanced into the right atrium via the puncture site, then subsequently crossing the tricuspid, right ventricle, and VSD to the left ventricle to build the delivery system. The guidewire was inserted through the hollow guide steel, and then the delivery system was introduced into the left ventricle along the guidewire after retraction of the hollow steel. We selected an appropriate device and loaded it into the loading sheath after immersing it in saline to squeeze the air out. We connected the delivery sheath to the loading sheath and pushed ahead by manipulating the cable. The left-side disc was opened first, and then we retracted the device and delivery sheath simultaneously. The right-side disc was open after the left-disc reached against the ventricular septum. When the double disc was placed into the defect, the to-and-fro closure attempt was done to confirm the stability of the device ( Figure  3) . The surrounding structures, especially the aortic valve and the tricuspid valve, were checked again by TEE. The device was released and the whole delivery system was withdrawn.
When TEE showed no complications, the thoracic area was closed as usual without a drainage tube.
The patients were administrated with aspirin (3-5 mg/kg per day) for 3-6 months immediately after operation. Physical examination, TTE, and ECG were done in outpatient setting during follow-up.
Follow-up Protocol
All patients were closely followed up at the time of 1, 3, 6, 12 months postoperatively and yearly thereafter. Adverse events were monitored in every patient by completing physical examination, TTE, and ECG.
Statistics Analysis
Data are expressed as frequency or percentage for normal variables; and mean ± standard deviation for continuous variables; median and range, as appropriate. All statistical analyses were performed by using IBM SPSS Statistics for Windows, Version 20.0 (released 2011; IBM Corp., Armonk, NY, USA).
RESULTS
Following the inclusion criteria, a total of 422 patients (209 male) successfully underwent transaxillary occluder device closure of the pmVSD solely guided by transesophageal echocardiography. The mean age of all patients was 2.2 ± 1.5 years (range 0.5-16.2 years), and the mean weight was 8.5 ± 4.1 kg (range 6-61 kg). During the procedure, the mean defect size measured by TEE was 4.2 ± 1.1 mm (range 3-6 mm), and the mean size of occluders implanted was 5.3 ± 1.4 (range 4-8 mm). The successful implantation of the device was achieved in 422 patients (98.6%), whereas failure happened in 6 patients (1.4%). All patients received an attempt to gain successful closure, except that 11 patients received The Heart Surgery Forum #2018-2185 E116 a closure attempt twice, and 2 patients received a closure attempt thrice. All preoperative moderate-to-severe tricuspid regurgitation disappeared. (Details are shown in Table 2 .)
Early Adverse Event Postoperatively
In 422 (98.6%) successful procedures, early adverse events emerged in 47 patients (11.1%), including left anterior block, complete right bundle branch block (CRBBB), incomplete right bundle branch block (IRBBB), and new aortic and tricuspid valve regurgitation.
The moment after the device was released, new mild tricuspid regurgitation was detected by TEE in 17 patients, and mild aortic regurgitation in 3 patients. No complete AVB occurred, except for several arrhythmia events, including LAD in one patient, CRBBB in 16 patients, and IRBBB in 6 patients; and all of them were administrated with close follow-up. A trivial residual shunt was detected in 3 patients, 1 mm, 1.5 mm, 1 mm, respectively, and was managed with close follow-up.
Pericardial effusion was found in 2 patients when they were transported to the general ward after extubation, and it was solved with tube drainage.
Conversion to Surgical Repair
Six patients (1.4%) failed to have device closure of the pmVSD. The reasons resulting in failure included new aortic valve regurgitation, inappropriate deployment, and severe resident shunt. Device-related aortic regurgitation appeared with an opening left disc impinging on the right aortic valve in 3 patients. In 3 patients, the left-to-right shunt showed no significant decrease by TEE, the defect of which was found irregular and oval; and the longest diameter could not be measured by TTE and TEE. The final patient of these 6 underwent device closure smoothly, but TTE in ICU showed the device had a big range of mobilization; the patient was transported with emergency to the operation room, and the device was proved dislocated. All 6 patients underwent open heart surgery uneventfully.
Follow-up Results
The follow-up was totally available for 408 patients (96.7%), whereas 4 patients missed the follow-up. The incision for this technique is minimal and can appear hidden in the armpit invisibly during follow-up (Figure 4) . The mean duration of follow-up was 36.8 months (range 6-60 months). No mortality and major adverse events were noted. Patients with frequent respiration infection had no recurrence; patients with failure to thrive had recovered in growth matched with development criteria; cardiomegaly resolved in all the followup patients.
During follow-up, the patients with arrhythmia had no aggravation. The patient with previous LAD recovered to healthy status; patients with CRBBB and IRBBB had no change without any relevant symptom. The mild tricuspid valve regurgitation in 17 patients disappeared except for 5 cases until the latest follow-up. Among 3 previous mild aortic valve regurgitation cases, 2 cases disappeared at 3rd-month follow-up, and the other one had no progress towards aggravation. All 3 patients with trivial residual shunt showed a complete closure at 3rd-month and 6th-month follow-ups. The 2 patients with pleural effusion before discharge had no recurrence by TTE at follow-up (details are shown in Table 3 ).
DISCUSSION
Traditional surgical repair on CPB has been considered the optimal choice for closure of the pmVSD, with excellent results, but simultaneously with risks of CPB, great trauma of midline sternotomy, and transfusion, each of which could pose a negative effect on postoperative recovery [Xing 2009; . Percutaneous transcatheter closure through use of fluoroscopy avoids CPB, great trauma, and transfusion; however, this technique needs expensive devices, which is not only impossible in a third world country, but also brings radiation damage to performers and patients. Besides, the advance of the guidewire and delivery sheath in vessels is invisible and could only be located by imagings of fluoroscopy, causing injuries to vessel endothelium. The transthoracic surgical device closure, combining merits of surgery and percutaneous transcatheter, has achieved excellent closure results since its introduction [Xing 2009; .
Transaxillary occluder device closure is performed via a right infra-axillary minimal incision, on the beating heart, under the guidance of TEE, avoiding CPB, great trauma, and radiation. Inferior median sternotomy is a common incision for transthoracic closure technique [Xing 2009; Xing 2010] . Though this incision has less trauma than median sternotomy, an obvious scar still is left on the chest wall. Different from inferior median sternotomy, the transaxillary approach adopts the infra-axillary minimal incision, the postoperative scar of which is hidden in the armpit, bringing both minimal effect and cosmetical aesthetics.
In this study, the use of the cavity bougie confirms the feasibility of the building of the delivery route. The technique, which goes from the right atrium to the left ventricle subsequently through the tricuspid valve and VSD, the route of which is tortuous, not straight, is different from traditional transthoracic technique with puncture of right free ventricle. In addition, the introduction of device deployment into the intracardiac structure from the right atrium avoids the injury of the right ventricular muscle and coronary arteries, which may be at risk of right ventricle dysfunction.
By reviewing previous literatures, we know that AVB is an extremely adverse event in all postoperative complications [Bai 2015 ]. We have not encountered such an adverse event of AVB from the beginning until the latest follow-up. Published reports show that the high incidence of occurrence was closely associated with transcatheter device closure, where a long loop delivery route and oversized and inflexible occluders were used, leading to compressure around the defect rim with radial force, especially on the conduction bunch running beneath the inferior rim of the defect [Xing 2015] . The occluders in this study were modified with more flexible materials, and generally the size of device was selected appropriately, ameliorating the compressure effect on defects' rims, which avoided interference with the conduction bunch going along the inferior rim of the defect; therefore, the AVB event is rare in transaxillary device closures. The total ECG events are CRBBB, and IRBBB, among which happened in only one patient and was relatively life-threatening. Fortunately, LAD disappeared at discharge.
Valve regurgitation is also a common complication postoperatively. Nine patients in this study with moderate-to-severe tricuspid regurgitation were included. Preoperative TTE showed that all tricuspid regurgitations of these patients were induced by left-to-right shunt, not caused by dysfunction of tricuspid valve. The operative result demonstrated that with a disappearance of tricuspid regurgitation. Although 17 mild tricuspid regurgitation cases were newly detected, the tricuspid regurgitation gradually disappeared during follow-up. Two mild preoperative aortic regurgitation cases, probably due to a hit on the aortic valve due to left-to-right shunt, disappeared after successful closure. Three new mild aortic regurgitation cases occurred, and we postulated that slight impinging on the right aortic leaflet contributed to this phenomenon. For them, we very closely followed them with respect to aortic regurgitation by TTE and found 2 patients relieved from aortic regurgitation, though one case remained until the latest follow-up. Therefore, we concluded that slight impinging could disappear with persistent mobility and form a relatively little interference between the left disc and the right aortic leaflet.
CONCLUSION
In our experience, the incidence of a serious adverse event is very low and has a successful rate, no lower than previous reports, confirming that the transaxillary occluder device closure of the pmVSD is a valuable alternative treatment in strictly selected pmVSD with promising early and midterm outcomes. Potential later onset conduction occurrence remains a common concern, so further follow-up study is needed to prove the latent risk factor for this technique.
